trans-Stilbene exhibits estrogenic activity in an estrogen reporter assay after metabolic activation. In this study, uterotrophic assay was conducted using ovariectomized B6C3F1/Crj female mice treated with trans-stilbene, trans-4-hydroxystilbene, trans-4,4′-dihydroxystilbene and diethylstilbestrol. Administration of trans-4-hydroxystilbene, trans-4,4′-dihydroxystilbene and diethylstilbestrol elicited increases in absolute and relative uterus weight. Furthermore, the uterine response caused by the hydroxylated stilbenes was accompanied with an increase in the thickness of epithelial cell layers. trans-Stilbene itself also showed estrogenic activity, affecting uterine weight and causing histological changes of the uterus. This suggests that trans-stilbene is activated to hydroxylated metabolites to exhibit its estrogenic activity. Indeed, trans-hydroxystilbenes were detected in the urine and feces of mice dosed with trans-stilbene. The effect of stilbene derivatives on testis in newborn B6C3F1/Crj mouse was examined. Administration of diethylstilbestrol slightly decreased the testis weight and atrophy of seminiferous tubules. However, transstilbene and trans-4-hydroxystilbene affected neither testis weight nor the histological appearance of the testis.
INTRODUCTION
Stilbene derivatives, such as diethylstilbestrol (DES), resveratrol, euvestin, 4,4′-diaminostilbene and pinosylvin, have a variety of biological actions, including hormonal, hypocholesterolemic, sympathomimetic, antifungal, antiallergic, antibacterial, antimalarial and anticancer activities. [1] [2] [3] [4] DES is the most well-known stilbene derivative, and has been used medically as a substitute for endogenous estrogen and as hormonal therapy for prostate or breast cancer, and also to prevent threatened abortions. 5, 6) However, it may induce vaginal adenocarcinoma. 7) Stilbene derivatives such as resveratrol (trans-4,3′,5′-trihydroxystilbene) are synthesized by stilbene synthase, which utilizes 3-malonyl-CoA and a starter CoA ester such as p-coumaroyl-CoA, in plants. 8, 9) Some hydroxystilbenes and their oligomeric derivatives play an important role as stilbenoid problems of the reproductive system in humans. In this study, we investigated potential estrogenic activities of trans-stilbene and its derivatives, including its metabolites, using in vivo uterotrophic assay in ovariectomized (OVX) female B6C3F1/Crj mouse. We also examined the influence of these compounds on testis in newborn male mouse.
MATERIALS AND METHODS
Chemicals ---17β-Estradiol was obtained from Sigma-Aldrich (St. Louis, MO, U.S.A.), trans-stilbene (99%) and DES (99%) from Tokyo Chemical Industry Co. Ltd. (Tokyo, Japan) and trans-4-hydroxystilbene (98%) from Lancaster Synthesis Ltd. (Lancashire, England). trans-4,4′-Dihydroxystilbene (mp. 275-278°C, 99% pure) was synthesized by the previously reported method.
15)
Animals ---Female B6C3F1/Crj, male C3H/ HeNCrj and female C57BL/6NCrj mice (20-22 g) were obtained from Charles River Japan (Hino, Japan). The animals were housed at 22°C with a 12-hr light/dark cycle, with free access to tap water and a standard pellet diet MF (Oriental Yeast, Tokyo, Japan). Uterotrophic Assay ---The procedure was based on the OECD protocol (OECD 1999). All animals were acclimatized to laboratory conditions for at least 1 week before ovariectomy, which was performed on 6-week-old animals. The ovary was pulled out and cut at the junction of the oviduct and the uterus body. After confirming that no massive bleeding had occurred, the abdominal wall was closed by a needle with strings and then skin by autoclips. All animals were allowed to acclimatize for at least 4 weeks after OVX. Test compounds (DES, trans-stilbene, trans-4-hydroxystilbene and trans-4,4′-dihydroxystilbene) were dissolved in Panacete 810 (a mixture of medium-chain triglycerides, Nippon Oils and Fats Co., Ltd., Tokyo, Japan) as a vehicle. All animals were dosed once per day for 3 days by intraperitoneal injection and were killed 24 hr after the last dose. Dosing solutions were prepared in Panacate at a concentration of 0.1, 1 or 3 mg/ml and used at a dosing volume of 0.2 ml/20 g body weight.
The dose level of DES, used as a positive control, was 0.1 mg/kg body weight. The body of the uterus was cut just above its junction with the cervix and at the junction of the uterus horns, and weighed. The uterus was placed in 10% buffered formalin solution, and paraffin sections were prepared. They were stained with an anti-PCNA antibody (Dako Co., Kyoto, Japan) used with the avidin-biotin complex method, and stained with hematoxylin and eosin for histological examination. Effect of Stilbenes on Testis ---Male C3H/ HeNCrj mice were mated with female C57BL/6NCrj mice for 1 week for the purpose of copulation. The newborn pups on postnatal day 1 (PND1) were dosed once by subcutaneous injection. Dosing solutions were prepared in Panacete at a concentration of 100 or 300 mg/ml and used at a dosing volume of 0.02 ml/2 g body weight. The dose levels of DES, used as a positive control, were 3 and 30 mg/kg body weight. After 8 weeks, all animals were killed, and testes were taken. In addition, one testis from each mouse was fixed in Bouin solution containing saturated picric acid solution, 5% formalin and 1% acetic acid for 24 hr. Paraffin sections were prepared and stained with hematoxylin and eosin for histological examination. Determination of in Vivo Metabolites of trans-Stilbene in Mice ---trans-Stilbene was given intraperitoneally to male mice at a single dose of 50 mg/ kg. Collected urine (1 ml) was supplemented with 0.1 ml of 2 N HCl and 0.1 µmol of phenothiazine (an internal standard). The urine was extracted twice with two volumes of ethyl acetate and the combined extracts were evaporated to dryness. The extract was analyzed by high-performance liquid chromatography (HPLC). The urine (1 ml) was also incubated with β-glucuronidase 3000 units/arylsulfatase 24000 units in 1 ml of 0.1 M citrate-phosphate buffer (pH 6.0) at 37°C for 16 hr. After the incubation, the mixture was extracted as described above. The feces (1 g) were dried, pulverized in a mortar and extracted twice with 10 volumes of methanol by sonication and shaking for 20 min each. The combined extracts were passed through a Florisil (Wako Pure Chemical Industries Ltd., Osaka, Japan, 5 × 30 mm) column, and analyzed by HPLC, using a Hitachi L-6000 chromatograph (Tokyo, Japan) fitted with a 250 × 4.6 mm Shiseido Capcell Pak C18 type UG 120A 5 µm column (Shiseido Co., Ltd. Tokyo, Japan). The mobile phase was acetonitrile-water (1 : 1, v/v). The chromatograph was operated at a flow rate of 1.0 ml/min at a wavelength of 254 nm. The elution times of trans-4,4′-dihydroxystilbene, trans-4-hydroxystilbene, phenothiazine (an internal standard) and trans-stilbene were 5.5, 15.3, 22.2 and 56.5 min, respectively. Statistics ---Results are expressed as the mean ± S.D. Multiple comparison was made by analysis of variance (ANOVA) followed by Scheffe's test.
RESULTS

Uterotrophic Test of Stilbene and Related Compounds
Previously, we reported that trans-stilbene was oxidized to 4-hydroxyl and 4,4′-dihydroxyl derivatives by cytochrome P450 1A1/2 in rat liver microsomes, and was thereby activated to exhibit estrogenic activity. 15, 16) Fifty percent effective concentration values (EC50) of 17β−estradiol, trans-4-hydroxystilbene and trans-4,4′-dihydroxystilbene in estrogen responsive element (ERE) luciferase reporter assay using MCF-7 were 1.3 × 10 -12 M, 1.0 × 10 -7 M and 8.0 × 10 -8 M, respectively. 17) To confirm the estrogenic potential of trans-stilbene and its metabolites in female reproductive tract, we evaluated the uterotrophic activities of trans-stilbene, trans-4-hydroxystilbene, trans-4,4′-dihydroxystilbene, and DES as a positive control using the test protocol recommended by the OECD (1999). These compounds were intraperitoneally injected once per day for 3 days into OVX mouse. As shown in Fig. 1 , trans-4-hydroxystilbene and trans-4,4′-dihydroxystilbene increased the uterus weight at 1.0 mg/kg/day or higher concentrations. DES (0.1 mg/kg/day) caused an increase in uterus weight of approximately threefold compared to control (Panacete-treated) mice. On the other hand, administration of trans-stilbene (100 mg/kg) significantly increased uterus weight.
Histological Changes of Uterus of Mice Dosed with Stilbenes
Histological changes in uterus of OVX mouse induced by 3-day treatment with DES and other stilbene derivatives were examined. Administration of DES, trans-4-hydroxystilbene and trans-4,4′-dihydroxy-stilbene increased the luminal epithelial height and the thickness of the stromal layers in the uterus. Treatment with trans-stilbene (100 mg/kg/ day) also altered the histological phenotype in the epithelial cells in OVX mouse (Figs. 2 and 3 ). As illustrated in Fig. 4 , there was a high correlation between uterus weight and the thickness of epithelium in OVX mouse treated with stilbene derivatives.
Effect of Stilbenes on Newborn Pups
To evaluate the effect of stilbene derivatives on testis, these compounds were administered to newborn pups on PND1 by subcutaneous injection, and testis weights were measured after 8 weeks (Fig. 5) . Administration of DES (3 and 30 mg/kg) caused a slight decrease in testis weight. However, trans-stilbene and trans-4-hydroxystilbene did not affect testis weight. The group treated with trans-4,4′-dihydroxystilbene died within 1 week after treatment. Fig. 6 shows the histological changes in testis of mouse induced by treatment with DES, trans-stilbene and trans-4-hydroxystilbene. DES (3 and 30 mg/kg) induced atrophy of seminiferous tubes, and tubular atrophy in seminiferous tubules (Fig. 7) . trans-Stilbene and trans-4-hydroxystilbene did not alter the histological phenotype in testis at this dosage. When these compounds were subcutaneously injected once into mature mouse, none of them caused any change in the weight or histology of the testis (data not shown).
in Vivo Metabolism of trans-Stilbene
When trans-stilbene was intraperitoneally administered to male mice, trans-stilbene and its metabolites were detected in the HPLC chromatogram of the urine and feces extracts. Retention times of the peaks corresponded to those of authentic transstilbene, trans-4-hydroxystilbene and trans-4,4′-dihydroxystilbene. The identity of these hydroxylated metabolites isolated by HPLC was confirmed by comparison of the mass and UV spectra with those of authentic samples (data not shown). The amounts of the metabolites excreted in the urine and feces are shown in Table 1 . Conjugated hydroxylated metabolites were determined after treatment of the urine with β-glucuronidase/arylsulfatase. The results are consistent with view that trans-stilbene exhibits estrogenic activity after activation to its hydroxylated metabolites in vivo.
DISCUSSION
trans-Stilbene is used as an industrial raw material for stilbene dyes and fluorescent brightening agents, and its derivatives, such resveratrol, are biosynthesized in plants in response to fungal attack or other stress conditions. 9) Previously, we presented evidence that trans-stilbene is converted to an active estrogen by liver microsomal enzymes. The estrogenic activity of trans-stilbene in rats in vivo seems to be a typical example of the metabolic activation of a proestrogen. It will be necessary to consider the activity of metabolites produced from the parent compounds for the assessment of the toxicity of stilbene derivatives. In rats and rabbits in vivo, trans-4-hydroxystilbene, trans-4,4′-dihydroxystilbene and trans-3,4,4′-trihydroxystilbene have been found as urinary metabolites of trans-stilbene. 18) 4,4′-Dihydroxydibenzyl was also identified as a metabolite. 19) We have also found that in mouse, transstilbene is converted to trans-4-hydroxystilbene and trans-4,4′-dihydroxystilbene, and to their glucuronide-or sulfate-conjugated metabolites as shown in the metabolism of resveratrol. 20) Interconversion between trans-stilbene and trans-stilbene oxide may also occur. 21) trans-Stilbene seems to be transformed by cytochrome P450 1A1/2 to hydroxylated metabolites, which exhibit estrogenic activity in vivo (Fig. 8) .
The uterotrophic action of estrogenic compounds in OVX mouse increases the uterus wet weight, which is an end point utilized in the standard in vivo assay for estrogenicity. Uterus wet weight and cytological changes have been used extensively as indicators of uterus response to estrogen-like effects. 22) In fact, trans-4-hydroxystilbene and trans-4,4′-dihydroxystilbene, as well as DES, caused increases in uterus weight and thickness of epithelium. Since these were a high correlation between the changes of uterus weight and thickness of epithelium, we suggest that the increase in uterus weight is largely attributable to the increase in thickness of epithelum 
trans-4-hydroxystilbene
and trans-4,4′-dihydroxystilbene. 15) ICI 182780 also inhibited estrone-stimulated uterine weight increase in OVX mouse. 24) These findings suggest that the uterotrophic effects of trans-4-hydroxystilbene and trans-4,4′-dihydroxystilbene are mediated through the estrogen receptor. Xeno-estrogenicity has been reported to be related to the presence of a phenolic ring, since phenolic compounds interact with the estrogen receptor in a similar manner to endogenous estrogens. [25] [26] [27] Treatment with trans-stilbene at the high dose of 100 mg/kg increased uterus weight and thickness of the epithelium, suggesting that trans-stilbene may be a proestrogen that is activated to trans-4-hydroxystilbene and trans-4,4′-dihydroxystilbene via aromatic hydroxylation by cytochrome P450. However, these metabolites would be rapidly conjugated in vivo to inactive forms, as reported in bisphenol A and p-tert-octylphenol. [28] [29] [30] This may be the reason why trans-stilbene exhibited estrogenic activity in vivo only at a high dose. Other potentially proestrogenic aromatic compounds that may be activated to estrogens by hydroxylation in vivo include methoxychlor, benzophenone, benzo[a]pyrene, diphenyl, 2-nitrofluorene and styrene oligomers. [31] [32] [33] [34] [35] [36] [37] These compounds, which are owing to absorption. There is a brief report that transstilbene showed a positive estrus response on vaginal smears in OVX rats after six doses of 25 mg/kg over three days. 23) In MCF-7 luciferase reporter assay, ICI 182780, a pure estrogen receptor antagonist, markedly inhibited the estrogenic activity of present as enviromental pollutants are negative in estrogen screening tests, but the possibility should be considered that they may also be metabolically activated to xeno-estrogens via hydroxylation in the body. Much further work is needed to identify potentially hazardous proestrogens in our environment.
We also investigated the effect of stilbene derivatives on testis in male newborn mouse. When DES was administered at a dose of 3 or 30 mg/kg, decreased testis weight and vacuolation of spermatids in the testis were seen at 8 weeks after the treatment. Furthermore, we observed tubular atrophy. Marked atrophy of the seminiferous tubules has been observed in the testis of rats exposed to dibromoacetic acid and 1,3-dinitrobenzene, which are thought to be non-estrogenic. 38, 39) Estradiol decreased testicular spermatid numbers and epididymal sperm numbers, and caused atrophy of epididymal tubules in male rats given ppm-level dietary exposure. 40) It is also known that neonatal exposure to DES (0.37 mg/kg/day or less for 18 days) can alter the structure of the testicular excurrent ducts, while change in testis weight, distension of the rete testis and efferent ducts, changes of epithelial cell height in the efferent ducts and immunoexpression of the water channel aquaporin-1 have been observed in adult rats. 41 ) However, we did not observe the above end points. Frederick et al. 42) reported that DES induced prostate enlargement in mice subjected to low-dose fetal exposure, but inhibited prostate Each value represents the mean of three animals. TS was given intraperitoneally to male mice at a single dose of 50 mg/kg. The extract of urine and feces was analyzed by HPLC. Conjugated metabolites were determined after treatment of the urine with ¬-glucuronide/arylsulfatase. development at high doses. It is difficult to establish whether these effects were direct or indirect. Our current study at least indicates that exposure to DES at high dose causes testicular damage in newborn mouse. On the other hand, administration of transstilbene and trans-4-hydroxystilbene had no detectable effect on any parameter examined. It is difficult to assess the action of these chemicals on testis unlike uterotrophic assay, because of the effect of the blood-testis barrier and the influence of negative feedback by the hypothalamus-pituitary system. Administration of stilbene derivatives to adult mouse did not cause histological changes. We suggest that hydroxylated stilbenes such as trans-4-hydroxystilbene and DES are transformed to nonestrogenic conjugates in vivo, because adults have a greater capacity for conjugation as compared with newborn mouse. However, there may be differences in metabolism between DES and hydroxylated stilbenes.
In conclusion, administration of trans-4-hydroxystilbene and trans-4,4′-dihydroxystilbene, metabolites of trans-stilbene, increased uterus weight in OVX mouse. Non-estrogenic trans-stilbene may be converted to estrogenic hydroxystilbene in vivo.
